ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)
ISSN 2383-9457 (ONLINE)
| Crude OR | p-value | Adjusted OR | p-value | |
|---|---|---|---|---|
| Sex | ||||
| male | 1.00[Reference] | 1.00[Reference] | ||
| female | 1.058[0.670-1.671, 95% CI] | 0.8073 | 0.981[0.575-1.673, 95% CI] | 0.9437 |
| Age | ||||
| <65 | 1.00[Reference] | 1.00[Reference] | ||
| ≥65 | 1.277[0.804-2.028, 95% CI] | 0.3001 | 1.143[0.667-1.958, 95% CI] | 0.6276 |
| Insurance type | ||||
| Health insurance | 1.00[Reference] | 1.00[Reference] | ||
| Others | 0.760[0.230-2.513, 95% CI] | 0.7743 | 0.760[0.230-2.513, 95% CI] | 0.6531 |
| Type of healthcare facility | ||||
| Tertiary general hospital | 1.00[Reference] | 1.00[Reference] | ||
| Others | 1.193[0.703-2.023, 95% CI] | 0.5133 | 0.855[0.453-1.615, 95% CI] | 0.6300 |
| Region | ||||
| Seoul | 1.00[Reference] | 1.00[Reference] | ||
| Metropolitan | 0.703[0.383-1.291, 95% CI] | 0.1603 | 0.508[0.246-1.049, 95% CI] | 0.0933 |
| Non-Metropolitan | 1.130[0.670-1.905, 95% CI] | 0.2526 | 0.842[0.450-1.577, 95% CI] | 0.5954 |
| Chemotherapy | ||||
| CHOP-based therapy | 1.00[Reference] | 1.00[Reference] | ||
| ABVD | 0.082[0.020-0.338, 95% CI] | 0.0005 | 0.086[0.019-0.388, 95% CI] | 0.0017 |
| Daunorubicin+cytarabine-based therapy | 0.041[0.004-0.431, 95% CI] | 0.0078 | 0.028[0.003-0.316, 95% CI] | 0.005 |
| Others | 0.107[0.054-0.213, 95% CI] | <.0001 | 0.086[0.041-0.180, 95% CI] | <.0001 |
| NCI comorbidity index | ||||
| 0 | 1.00[Reference] | 1.00[Reference] | ||
| 1 | 0.843[0.478-1.485, 95% CI] | 0.2000 | 0.575[0.294-1.127, 95% CI] | 0.1608 |
| 2 | 0.590[0.206-1.687, 95% CI] | 0.0906 | 0.430[0.122-1.518, 95% CI] | 0.1338 |
| ≥3 | 4.717[1.046-21.263, 95% CI] | 0.0224 | 3.040[0.607-15.226, 95% CI] | 0.0604 |